Monia C.
- Country
- Italy
- Department
- Hematology
Research Overview
- Phase 3 Randomized Study of Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular and Marginal Zone Lymphoma
- An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi
- A Phase 3 Randomized Study Comparing Odronextamab and Lenalidomide Versus Rituximab and Lenalidomide in Relapsed/Refractory Follicular and Marginal Zone Lymphoma
Data & Insights
Has run more than one trial at 73 of 218 partner sites.
Specializations
Hematologic malignancies
Clinical research activity is centered on acute myeloid leukemia, acute lymphoblastic leukemia, and a broad spectrum of B-cell lymphomas, including chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, mantle cell-related rare B-cell disorders, and hairy cell leukemia.
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
- Follicular lymphoma
- Rare B-cell malignancies
The therapeutic focus also includes cellular therapy, targeted treatment, and immunotherapy for relapsed or high-risk blood cancers.
Thoracic oncology
Investigational work spans non-small cell lung cancer and small cell lung cancer, with attention to advanced, metastatic, resectable, and post-chemoradiation disease settings, including tumors with ALK rearrangement, EGFR mutation, KRAS G12C, and PD-L1 selection.
- Non-small cell lung cancer
- Small cell lung cancer
- ALK-positive disease
- Advanced lung cancer
Therapeutic interests include antibody-based oncology, antibody-drug conjugates, and post-operative or consolidation treatment strategies in lung cancer.
Melanoma and solid tumors
The investigator is involved in studies of melanoma, cutaneous squamous cell carcinoma, urothelial carcinoma, renal cell carcinoma, pancreatic cancer, and other advanced solid tumors, including biomarker-defined disease.
- Melanoma
- Cutaneous squamous cell carcinoma
- Urothelial carcinoma
- Renal cell carcinoma
Key therapeutic domains include checkpoint inhibition, bispecific immunotherapy, and targeted treatment for genomic alterations.
Autoimmune and inflammatory disease
Research activity also extends to atopic dermatitis, prurigo nodularis, hidradenitis suppurativa, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s disease, and polymyalgia rheumatica.
- Atopic dermatitis
- Prurigo nodularis
- Hidradenitis suppurativa
- Autoimmune rheumatic disease
The therapeutic landscape includes immune modulation, anti-inflammatory treatment, and management of chronic immune-mediated skin and systemic disorders.
Cardiometabolic, neurologic, and ophthalmic disorders
Additional interests cover atherosclerotic cardiovascular disease, atrial fibrillation, heart failure with reduced ejection fraction, stroke prevention, type 2 diabetes, Alzheimer’s disease, and neovascular age-related macular degeneration.
- Atherosclerotic cardiovascular disease
- Atrial fibrillation
- Type 2 diabetes
- Alzheimer’s disease
Therapeutic involvement includes antithrombotic therapy, metabolic disease management, neurodegenerative disease treatment, and retinal disease intervention.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.